Literature DB >> 21445565

Enhancement of serotonergic and noradrenergic neurotransmission in the rat hippocampus by sustained administration of bupropion.

Ramez Ghanbari1, Mostafa El Mansari, Pierre Blier.   

Abstract

RATIONALE: Previous studies reported that bupropion, an effective antidepressant, exerts modulatory actions on serotonin (5-HT) and norepinephrine (NE) neurons.
OBJECTIVES: This study examined effects of bupropion administration on 5-HT and NE neurotransmission in hippocampus.
METHODS: Electrophysiological recordings were obtained from anesthetized Sprague-Dawley rats. Subcutaneously implanted minipumps delivered saline or bupropion (30 mg/kg/day) for 2 and 14 days.
RESULTS: Although sustained bupropion administration did not alter the sensitivity of 5-HT(1A) and α₂-adrenergic receptors, the tonic activation of postsynaptic 5-HT(1A) receptors by endogenous 5-HT was enhanced in 14-day bupropion-treated rats to a greater extent than in the 2-day and control rats, as revealed by the greater disinhibitory action of the 5-HT(1A) antagonist WAY-100635 on hippocampus pyramidal neurons. The function of terminal 5-HT(1B) autoreceptors was not changed as determined by the unaltered effectiveness of different frequencies of stimulation of the ascending 5-HT fibers. The function of α₂-adrenergic receptors on 5-HT terminals was, however, diminished, as indicated by the lesser effect of the α₂-adrenoceptor agonist clonidine. Tonic activation of postsynaptic α₂- and α₁-adrenoceptors by endogenous NE was also increased in 14-day bupropion-treated rats, as indicated by the greater effect of the α₂- and α₁-adrenoceptor antagonists idazoxan and prazosin, respectively, on pyramidal firing. The function of terminal α₂-adrenergic autoreceptors was attenuated since increasing frequency of stimulation of the ascending NE pathway produced a lesser degree of suppression of pyramidal neurons in rats administered bupropion than the control.
CONCLUSION: Enhancement of 5-HT and NE transmissions in hippocampus by prolonged bupropion may account for its effectiveness in major depression.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21445565     DOI: 10.1007/s00213-011-2260-1

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  55 in total

Review 1.  Use of bupropion in combination with serotonin reuptake inhibitors.

Authors:  Sidney Zisook; A John Rush; Barbara R Haight; Dawn C Clines; Carol B Rockett
Journal:  Biol Psychiatry       Date:  2005-09-13       Impact factor: 13.382

2.  Involvement of alpha-receptors in clonidine-induced inhibition of transmitter release from central monoamine neurones.

Authors:  K Starke; H Montel
Journal:  Neuropharmacology       Date:  1973-11       Impact factor: 5.250

3.  Down regulation of beta-receptors by bupropion and its major metabolite in mouse brain.

Authors:  A S Perumal; T M Smith; R F Suckow; T B Cooper
Journal:  Neuropharmacology       Date:  1986-12       Impact factor: 5.250

4.  In vivo electrophysiological evidence for the regulatory role of autoreceptors on serotonergic terminals.

Authors:  Y Chaput; P Blier; C de Montigny
Journal:  J Neurosci       Date:  1986-10       Impact factor: 6.167

5.  Pharmacological characterization of presynaptic alpha-adrenoceptors modulating [3H]noradrenaline and [3H]5-hydroxytryptamine release from slices of the hippocampus of the rat.

Authors:  A L Frankhuyzen; A H Mulder
Journal:  Eur J Pharmacol       Date:  1982-06-16       Impact factor: 4.432

6.  Binding of antidepressants to human brain receptors: focus on newer generation compounds.

Authors:  B Cusack; A Nelson; E Richelson
Journal:  Psychopharmacology (Berl)       Date:  1994-05       Impact factor: 4.530

7.  Evidence that the acute behavioral and electrophysiological effects of bupropion (Wellbutrin) are mediated by a noradrenergic mechanism.

Authors:  B R Cooper; C M Wang; R F Cox; R Norton; V Shea; R M Ferris
Journal:  Neuropsychopharmacology       Date:  1994-10       Impact factor: 7.853

8.  Neurochemical and psychotropic effects of bupropion in healthy male subjects.

Authors:  Gabriella Gobbi; Susan Slater; Nathalie Boucher; Guy Debonnel; Pierre Blier
Journal:  J Clin Psychopharmacol       Date:  2003-06       Impact factor: 3.153

9.  Opiate and alpha 2-adrenoceptor responses of rat amygdaloid neurons: co-localization and interactions during withdrawal.

Authors:  J E Freedman; G K Aghajanian
Journal:  J Neurosci       Date:  1985-11       Impact factor: 6.167

10.  Electrophysiological effects of the co-administration of escitalopram and bupropion on rat serotonin and norepinephrine neurons.

Authors:  R Ghanbari; M El Mansari; P Blier
Journal:  J Psychopharmacol       Date:  2008-08-21       Impact factor: 4.153

View more
  9 in total

1.  Effects of sustained administration of quetiapine alone and in combination with a serotonin reuptake inhibitor on norepinephrine and serotonin transmission.

Authors:  Olga Chernoloz; Mostafa El Mansari; Pierre Blier
Journal:  Neuropsychopharmacology       Date:  2012-02-29       Impact factor: 7.853

2.  Interaction of antidepressant and antipsychotic drugs with the human organic cation transporters hOCT1, hOCT2 and hOCT3.

Authors:  Britta Haenisch; Eva Drescher; Lidia Thiemer; Hu Xin; Bruno Giros; Sophie Gautron; Heinz Bönisch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-07-18       Impact factor: 3.000

3.  General and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders: a report by the WPA section of pharmacopsychiatry.

Authors:  Thomas C Baghai; Pierre Blier; David S Baldwin; Michael Bauer; Guy M Goodwin; Kostas N Fountoulakis; Siegfried Kasper; Brian E Leonard; Ulrik F Malt; Dan Stein; Marcio Versiani; Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-11       Impact factor: 5.270

4.  In Response to Borgsteede et al. About Bupropion and Serotonin Toxicity.

Authors:  Brian Patrick Murray; Joseph Carpenter; Tim P Moran; Diane P Calello; Ziad Kazzi
Journal:  J Med Toxicol       Date:  2020-03-03

Review 5.  Serotonin and beyond: therapeutics for major depression.

Authors:  Pierre Blier; Mostafa El Mansari
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2013-02-25       Impact factor: 6.237

6.  Single-Agent Bupropion Exposures: Clinical Characteristics and an Atypical Cause of Serotonin Toxicity.

Authors:  Brian Murray; Joseph Carpenter; Camille Dunkley; Tim P Moran; Emily A Kiernan; Tony Rianprakaisang; Waleed S Alsukaiti; Diane P Calello; Ziad Kazzi
Journal:  J Med Toxicol       Date:  2019-12-10

7.  Restoration of serotonin neuronal firing following long-term administration of bupropion but not paroxetine in olfactory bulbectomized rats.

Authors:  Mostafa El Mansari; Stella Manta; Chris Oosterhof; Kareem S El Iskandrani; Franck Chenu; Stacey Shim; Pierre Blier
Journal:  Int J Neuropsychopharmacol       Date:  2014-10-31       Impact factor: 5.176

8.  Brexpiprazole Alters Monoaminergic Systems following Repeated Administration: an in Vivo Electrophysiological Study.

Authors:  Chris A Oosterhof; Mostafa El Mansari; Christoffer Bundgaard; Pierre Blier
Journal:  Int J Neuropsychopharmacol       Date:  2015-10-01       Impact factor: 5.176

9.  Molecular basis of atypicality of bupropion inferred from its receptor engagement in nervous system tissues.

Authors:  Eric J Kim; Klara Felsovalyi; Lauren M Young; Sergey V Shmelkov; Michael F Grunebaum; Timothy Cardozo
Journal:  Psychopharmacology (Berl)       Date:  2018-07-01       Impact factor: 4.530

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.